alpha-MSH analog is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Reconstitution is required before use in most assays |
| Solubility class | Freely soluble in water and acetonitrile; sparingly soluble in nonpolar solvents | Aqueous solutions may benefit from slight acidification |
| Typical storage temperature | -20 °C or lower, desiccated and protected from light | Short-term transport at 2-8 °C is common practice |
| Primary degradation routes | Oxidation, hydrolysis, aggregation | Tryptophan and histidine residues are the main oxidation targets |
| Quality marker | Chromatographic purity by peak area | Does not capture counter-ion content or residual solvents |
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
immortalization The natural or artificial changing of a cell population with a normally finite lifespan into one with a hypothetically infinite lifespan, capable of dividing indefinitely without cellular senescence as long as essential nutrients are available and conditions are conducive for cell division. Cells that undergo such a change are said to be immortalized. Mutations that cause immortalization occur naturally in the neoplasms that cause cancer but can also be induced artificially, which makes it possible to culture certain cell lines in vitro for prolonged periods. Immortalized cell lines are thus broadly useful for experimental purposes and in many biotechnology applications. Immortalized eukaryotic cells are commonly obtained by isolating them from a naturally occurring neoplasm (as with the human HeLa cell line), or may be generated from normal cells by introducing viral genes (as with HEK 293 cells), by artificially overexpressing proteins required for immortality such as telomerase, or by fusing normal cells with cancer cells (as in the hybridoma technologies used in the commercial production of antibodies). Though stem cells are also capable of continuous self-renewal and are thus technically 'immortal', their immortalization is not abnormal because they are an ordinary part of the development of multicellular organisms.
HClO ⇌ ClO− + H+ Salts of hypochlorous acid are called hypochlorites. One of the best-known hypochlorites is NaClO, the active ingredient in bleach. HClO is a stronger oxidant than chlorine under standard conditions.
The electrostatic sector may be before or after the magnetic sector depending on the particular instrument, and reduces the spread in kinetic energy caused by the plasma. This spread is particularly large for ICP-MS, being larger than Glow Discharge and much larger than TIMS. The geometry of the instrument is chosen so that the instrument the combined focal point of the electrostatic and magnetic sectors is at the collector, known as Double Focusing (or Double Focussing). If the mass of interest has a low sensitivity and is just below a much larger peak, the low mass tail from this larger peak can intrude onto the mass of interest. A Retardation Filter might be used to reduce this tail. This sits near the collector, and applies a voltage equal but opposite to the accelerating voltage; any ions that have lost energy while flying around the instrument will be decelerated to rest by the filter.
Sources: en.wikipedia.org
=== Traditional method === Dried and cleaned stomachs of young calves are sliced into small pieces and then put into salt water or whey, together with some vinegar or wine to lower the pH of the solution. After some time (overnight or several days), the solution is filtered. The crude rennet that remains in the filtered solution can then be used to coagulate milk. About 1 gram of this solution can normally coagulate 2 to 4 litres of milk.
Having united these two complex fragments, Still was able to complete the synthesis of monensin in three additional steps. First, hydrogenolysis of the benzyl group afforded the free primary alcohol under standard conditions. Next, cleavage of the triethylsilyl (TES) protecting groups was achieved in the presence of para-toluenesulfonic acid; the resulting free secondary alcohols then engaged the ketone in a spontaneous cyclization reaction to form the thermodynamic spiroketal linkage. Finally, hydrolysis of the methyl ester under basic conditions furnished the sodium salt of monensin, completing the synthesis of this challenging natural product.
Teacher of Mathematics, Grange Academy, Kilmarnock. For services to Mathematics Education and to the community in East Ayrshire. Professor Matthew David Snape. Lately Professor in Paediatrics and Vaccinology, Oxford Vaccine Group, University of Oxford. For services to Public Health, particularly during Covid-19. Ellen Somme. Founder, Teddy Trust. For services to Vulnerable Children. Keith Wyn Sorrell. Lately Chief Executive Officer, Windsor Academy Trust. For services to Education. Stephen Terence Sorrell. Director, Small Things Creative Projects Community Interest Company. For services to Arts and Culture in Greater Manchester. Julie Spencer. Head of Student Wellbeing Service, University of Lincoln. For services to Education. Karen Eleanor Spiers. Senior Charge Nurse, NHS Lanarkshire. For services to Dementia Care in Hospital. Robert Jeffrey Stelling. Lately Broadcaster, Sky Sports. For services to Sport, to Broadcasting and to Charity. Richard Alexander Stewart. Lately Trustee and Chair of Trustees, St. John's School and College. For services to Children and Young People with Special Educational Needs and Disabilities. Amanda St John Davey. National Chair, Women in Property. For services to Working Women. Dr. Andrew Stott. Lately Science Adviser, Department for Environment, Food and Rural Affairs. For services to Nature and Climate. Professor Peter Alister Stott. Deputy Head of Climate Science and Science Fellow, Met Office. For services to Climate Science. The Reverend Professor Elizabeth Bridget Stuart. Lately Deputy Vice-Chancellor, University of Winchester.
==== Using detrital zircon age abundance ==== In a global scale, detrital zircon age abundance can be used as a tool to infer significant tectonic events in the past. In Earth's history, the abundance of magmatic age peaks during periods of supercontinent assembly. This is because supercontinent provides a major crustal envelop selectively preserve the felsic magmatic rocks, resulting from partial melts. Thus, many detrital zircons originate from these igneous provence, resulting similar age peak records. For instance, the peak at about 0.6–0.7 Ga and 2.7 Ga (Figure 6) may correlate the break-up of Rodinia and supercontinent Kenorland respectively.
Sources: en.wikipedia.org
Solutions are best kept cold, protected from light, and buffered to a pH that limits hydrolysis. Dividing a stock into single-use aliquots avoids repeated freeze-thaw cycles, which measurably reduce the intact parent peak over time.
Reversed-phase chromatography establishes a purity profile, while electrospray or matrix-assisted laser desorption mass spectrometry confirms that the observed mass matches the expected sequence. Together they support, but do not fully prove, identity and purity.
Reviews generally characterise it as thin, dominated by small and often uncontrolled studies. Several authors explicitly note that findings on pigmentation, appetite and sexual function have not been confirmed in adequately powered controlled trials.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.